Market Cap | 11.12M | P/E | - | EPS this Y | 20.40% | Ern Qtrly Grth | - |
Income | -31.75M | Forward P/E | -0.44 | EPS next Y | -3.30% | 50D Avg Chg | -26.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -43.00% |
Dividend | N/A | Price/Book | 0.92 | EPS next 5Y | - | 52W High Chg | -77.00% |
Recommedations | 1.50 | Quick Ratio | 2.14 | Shares Outstanding | 25.21M | 52W Low Chg | 7.00% |
Insider Own | 0.24% | ROA | -54.28% | Shares Float | 21.51M | Beta | -2.88 |
Inst Own | 22.43% | ROE | -289.26% | Shares Shorted/Prior | 1.92M/2.11M | Price | 0.96 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 73,264 | Target Price | 18.60 |
Oper. Margin | - | Earnings Date | Nov 6 | Volume | 31,367 | Change | 4.35% |
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
HC Wainwright & Co. | Buy | Aug 15, 24 |
Piper Sandler | Overweight | Jun 21, 24 |
HC Wainwright & Co. | Buy | Jun 20, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
HC Wainwright & Co. | Buy | Mar 20, 24 |
Scotiabank | Sector Outperform | Mar 14, 24 |
Scotiabank | Sector Outperform | Mar 13, 24 |
HC Wainwright & Co. | Buy | Mar 12, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Woiwode Thomas | Director Director | Apr 29 | Buy | 2.36 | 2,118,644 | 5,000,000 | 2,118,644 | 05/03/22 |
Dubensky Thomas W. | President President | Jan 07 | Buy | 4.78 | 2,000 | 9,560 | 113,343 | 01/11/22 |
Whiting Samuel | Chief Medical Office.. Chief Medical Officer | Jan 06 | Buy | 4.8048 | 1,700 | 8,168 | 1,901 | 01/10/22 |